This study focuses on Diffuse Large B-cell Lymphoma, which is a type of blood cancer that affects white blood cells. The research is specifically for individuals whose cancer has Relapsed or refractory, meaning the cancer has returned after treatment or has stopped responding to initial therapies. The purpose of the study is to compare the effectiveness of a new treatment combination against a standard treatment combination.

Participants in the study will receive one of two different treatment paths. One group will receive glofitamab along with gemcitabine and oxaliplatin. The other group will receive rituximab combined with gemcitabine and oxaliplatin. These medications are administered through an IV infusion, which is a method where medicine is delivered directly into a vein using a needle or a small tube.

During the course of the study, the health and response to the treatments will be monitored. The study will track how long patients live and how long they live without the disease getting worse. Researchers will also look for side effects, such as cytokine-release syndrome, which is a temporary reaction where the body’s immune system becomes overly active. The study involves regular check-ups to observe how the medications affect the body and the cancer.